Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation

Andreas H. Groll*, Elio Castagnola, Simone Cesaro, Jean Hugues Dalle, Dan Engelhard, William Hope, Emmanuel Roilides, Jan Styczynski, Adilia Warris, Thomas Lehrnbecher

*Corresponding author for this work

Research output: Contribution to journalArticle

219 Citations (Scopus)

Abstract

Invasive opportunistic fungal diseases (IFDs) are important causes of morbidity and mortality in paediatric patients with cancer and those who have had an allogeneic haemopoietic stem-cell transplantation (HSCT). Apart from differences in underlying disorders and comorbidities relative to those of adults, IFDs in infants, children, and adolescents are unique with respect to their epidemiology, the usefulness of diagnostic methods, the pharmacology and dosing of antifungal agents, and the absence of interventional phase 3 clinical trials for guidance of evidence-based decisions. To better define the state of knowledge on IFDs in paediatric patients with cancer and allogeneic HSCT and to improve IFD diagnosis, prevention, and management, the Fourth European Conference on Infections in Leukaemia (ECIL-4) in 2011 convened a group that reviewed the scientific literature on IFDs and graded the available quality of evidence according to the Infectious Diseases Society of America grading system. The final considerations and recommendations of the group are summarised in this manuscript.

Original languageEnglish
Pages (from-to)E327-E340
Number of pages14
JournalThe Lancet Oncology
Volume15
Issue number8
Early online date29 Jun 2014
DOIs
Publication statusPublished - Jul 2014

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation'. Together they form a unique fingerprint.

  • Cite this